Efficacy and safety of ultrasonography-guided radiofrequency ablation for the treatment of T1bN0M0 papillary thyroid carcinoma: a retrospective study

Abstract

Purpose To evaluate the efficacy and safety of ultrasonography (US)-guided radiofrequency ablation (RFA) for treating low-risk T1bN0M0 papillary thyroid cancer (PTC). Methods This retrospective study was approved by the ethics committee of the Chinese People’s Liberation Army General Hospital (S2019-211-01). Sixty-six patients with T1bN0M0 PTC (14 men and 52 women with a mean age of 41.0 ± 9.2 years [range, 21–61 years]), who were not eligible for or refused surgery, were included in our study. RFA was performed with the moving-shot technique, and the ablation area exceeded the tumor edge by at least 3 mm. US (including contrast-enhanced) was performed before RFA; 1, 3, and 6 months after RFA, and every 6 months thereafter. US-guided core-needle biopsy was performed 3 or 6 months after ablation to rule out recurrence. Results The technical success rate was 100%, and there were no major complications. The tumor volume decreased significantly; the volume reduction rate (VRR) was 99.11 ± 2.44% (range, 92.62–100%) at the final follow-up with 38 tumors (57.6%) disappearing. Significant decreases in the VRR were found at every other follow-up visit before 18 months (p < .01). Technique efficacy was obtained in 64/66 (97.0%) patients over 20.5 ± 7.4 months follow-up. Malignant cells were confirmed in 2 ablation zones (3.0%), and cervical lymph node metastasis was detected in 1 patient (1.5%). These patients underwent additional RFA and achieved good results. Conclusion RFA may be considered a safe and effective modality for the management of T1bN0M0 PTC in select patients.